CY1120475T1 - Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα - Google Patents

Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Info

Publication number
CY1120475T1
CY1120475T1 CY20181100757T CY181100757T CY1120475T1 CY 1120475 T1 CY1120475 T1 CY 1120475T1 CY 20181100757 T CY20181100757 T CY 20181100757T CY 181100757 T CY181100757 T CY 181100757T CY 1120475 T1 CY1120475 T1 CY 1120475T1
Authority
CY
Cyprus
Prior art keywords
indoli
pyrrolium
producers
preparing
new
Prior art date
Application number
CY20181100757T
Other languages
English (en)
Inventor
Patrick Casara
Thierry Le Diguarher
Jean-Michel Henlin
Jérôme-Benoît STARCK
Arnaud Le Tiran
Guillaume De Nanteuil
Olivier Geneste
James Edward Paul Davidson
James Brooke MURRAY
I-Jen Chen
Claire WALMSLEY
Christopher John GRAHAM
Stuart Ray
Daniel MADDOX
Simon Bedford
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1120475T1 publication Critical patent/CY1120475T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Ενώσεις του τύπου (I), όπου Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, Τ και W είναι όπως ορίζονται στην περιγραφή. Φάρμακα.
CY20181100757T 2013-07-23 2018-07-19 Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα CY1120475T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357277A FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051884 WO2015011396A1 (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CY1120475T1 true CY1120475T1 (el) 2019-07-10

Family

ID=49911607

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100757T CY1120475T1 (el) 2013-07-23 2018-07-19 Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Country Status (31)

Country Link
US (2) US9765056B2 (el)
EP (2) EP3027602B1 (el)
JP (1) JP6458028B2 (el)
KR (1) KR102337149B1 (el)
CN (1) CN105408321B (el)
AR (1) AR099914A1 (el)
AU (1) AU2014294866B2 (el)
BR (1) BR112016001333B1 (el)
CA (1) CA2917965C (el)
CY (1) CY1120475T1 (el)
DK (1) DK3027602T3 (el)
EA (1) EA028609B1 (el)
ES (1) ES2687475T3 (el)
FR (1) FR3008978A1 (el)
HK (1) HK1218753A1 (el)
HR (1) HRP20181333T1 (el)
HU (1) HUE039507T2 (el)
LT (1) LT3027602T (el)
MX (1) MX364479B (el)
NZ (1) NZ715847A (el)
PL (1) PL3027602T3 (el)
PT (1) PT3027602T (el)
RS (1) RS57545B1 (el)
RU (1) RU2693404C2 (el)
SG (1) SG11201600004SA (el)
SI (1) SI3027602T1 (el)
TW (1) TW201504224A (el)
UA (1) UA117020C2 (el)
UY (1) UY35653A (el)
WO (1) WO2015011396A1 (el)
ZA (1) ZA201600415B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237509A (zh) * 2015-11-20 2016-01-13 江苏瑞邦农药厂有限公司 一种2,2-二氟-1,3-苯并二恶茂的合成方法
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
JP6928096B2 (ja) * 2017-01-10 2021-09-01 イーティーエイチ・チューリッヒ 細胞保護化合物及びそれらの使用
TWI743346B (zh) 2017-03-31 2021-10-21 國立大學法人東京大學 諾羅病毒抗體
CN108409580A (zh) * 2018-02-01 2018-08-17 浙江工业大学 一种苄胺类化合物的合成方法
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060596A1 (en) 2003-10-24 2007-03-15 Giblin Gerard M P Heterocyclyl compounds
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
GB0522908D0 (en) 2005-11-10 2005-12-21 Merck Sharp & Dohme Therapeutic agents
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
KR20140107573A (ko) * 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
US20140357633A1 (en) * 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015308A8 (pt) * 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
MX2014007725A (es) * 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
BR112014015322A8 (pt) * 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2015011396A1 (fr) 2015-01-29
EP3027602B1 (fr) 2018-06-13
KR102337149B1 (ko) 2021-12-07
EA201600121A1 (ru) 2016-07-29
CN105408321A (zh) 2016-03-16
CA2917965A1 (fr) 2015-01-29
HK1218753A1 (zh) 2017-03-10
CN105408321B (zh) 2019-03-08
MX364479B (es) 2019-04-29
ES2687475T3 (es) 2018-10-25
RS57545B1 (sr) 2018-10-31
EP3168217A1 (fr) 2017-05-17
JP2016531108A (ja) 2016-10-06
UA117020C2 (uk) 2018-06-11
KR20160034384A (ko) 2016-03-29
LT3027602T (lt) 2018-07-25
CA2917965C (fr) 2018-03-06
AU2014294866A1 (en) 2016-02-04
AR099914A1 (es) 2016-08-31
SI3027602T1 (en) 2018-08-31
TW201504224A (zh) 2015-02-01
RU2016106002A3 (el) 2018-03-19
HRP20181333T1 (hr) 2018-10-19
BR112016001333B1 (pt) 2022-03-03
US9765056B2 (en) 2017-09-19
PT3027602T (pt) 2018-07-23
SG11201600004SA (en) 2016-02-26
FR3008978A1 (fr) 2015-01-30
EA028609B1 (ru) 2017-12-29
RU2016106002A (ru) 2017-08-30
US20160152599A1 (en) 2016-06-02
UY35653A (es) 2015-02-27
JP6458028B2 (ja) 2019-01-23
EP3027602A1 (fr) 2016-06-08
US10662173B2 (en) 2020-05-26
RU2693404C2 (ru) 2019-07-02
AU2014294866B2 (en) 2018-09-27
MX2016000900A (es) 2016-05-05
PL3027602T3 (pl) 2018-10-31
DK3027602T3 (en) 2018-09-24
BR112016001333A2 (el) 2017-07-25
NZ715847A (en) 2019-06-28
ZA201600415B (en) 2017-03-29
HUE039507T2 (hu) 2019-01-28
US20170342051A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CY1120475T1 (el) Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1119652T1 (el) Νεα παραγωγα ινδολιζινης, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1118756T1 (el) Νεα παραγωγα πυρρολιου, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
CY1118547T1 (el) Νεα παραγωγα ινδολιζινης, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν για τη θεραπεια του καρκινου
CY1118058T1 (el) Νεα παραγωγα θειενοπυριμιδινης, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1122560T1 (el) Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα
CY1123069T1 (el) Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1120991T1 (el) Νεα παραγωγα αμινοξεος, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1122542T1 (el) Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CY1120474T1 (el) Χημικες ενωσεις
CY1122870T1 (el) Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
DK3518892T3 (da) Farmaceutisk formulering, der indeholder en insulinforbindelse
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
CY1121247T1 (el) Νεες ενωσεις ισοϊνδολινης ή ισοκινολινης, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτες
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
IN2013MU00665A (el)
DK3081560T3 (da) Taxanforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf